Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Grant E. Pickering
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 507
- Beta
- 1.29
- Country
- US
- Piotroski score
- 0 / 9 (Weak)
- Altman Z-score
- 8.80
Financials
Net Income
$-297.06MEBITDA
$-291.28MFree Cash Flow
$-229.04MEPS (diluted)
$-1.99Shares Outstanding (diluted)
148.91M+3956.0%Operating Expenses
$308.27MCash & Debt
$1.29BRevenue by Segment (annual)
$7.00BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-766.63M | $-5.63 |
| 2024 | $0.00 | $-463.93M | $-3.80 |
| 2023 | $0.00 | $-402.27M | $-4.14 |
| 2022 | $0.00 | $-223.49M | $-3.44 |
| 2021 | $0.00 | $-100.08M | $-1.93 |
| 2020 | $0.00 | $-89.22M | $-2.97 |
| 2019 | $0.00 | $-50.27M | $-14.10 |
| 2018 | $0.00 | $-29.48M | $-8.12 |
| 2017 | $0.00 | $-17.24M | $-4.84 |
Valuation
PCVXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (33)
- Newszacks.com·23d ago·Positive
Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High? The mean of analysts' price targets for Vaxcyte (PCVX) points to an 87.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗ - News (RSS)seekingalpha·34d ago·Neutral
Vaxcyte: Vaccine Titan In The Making
View source ↗ - News (RSS)seekingalpha·46d ago·Neutral
Vaxcyte prices $500M equity offering and $500M convertible notes
View source ↗ - News (Marketaux)manilatimes.net·46d ago·Neutral
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes ., Oct. 06, 2026 (GLOBE NEWSWIRE) -- <em[+28 characters]
View source ↗ - Newsglobenewswire.com·47d ago·Negative
…rrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock, pre-funded warrants to purchase 400,000 shares of common stock and $500 million aggregate principal amount of 1.50% convertible senior notes due 2032 (the “notes”). The shar…
View source ↗ - News (RSS)seekingalpha·47d ago·Positive
Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027
View source ↗ - Newsseekingalpha.com·47d ago·Positive
Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027 Vaxcyte remains a 'Strong Buy' after robust phase 3 OPUS-1 results for VAX-31, demonstrating non-inferiority to Prevnar 20 and Capvaxive in adults. The company offers significant upside with multiple 2027 catalysts: OPUS-2 and OPUS-3 phase 3 data for VAX-31 in adults in the 1st half of 2027 and phase 2 infant data. VAX-31 targets broader pneumococcal strain coverage versus current vaccines, addressing emer…
View source ↗ - News (RSS)zerohedge·47d ago·Neutral
…ents linked to Huawei's LogicFolding tech. AMD CEO Lisa Su sees "very high" chip demand for the next few years. Spyre Therapeutics priced 4.12 million shares at $85. Vaxcyte plans an offering of convertible notes due 2032. Ambani's Jio is said to seek a valuation of about $114 billion in its IPO. LS Power raised $6 billion for its largest flagship fund, and Live Nation is looking to raise $1.4 billion in bonds, including its debut euro offering. And according to the New York State Comptroller, N…
View source ↗ - Newsmarketbeat.com·48d ago·Neutral
Vaxcyte's VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial Vaxcyte NASDAQ: PCVX said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial in adults.
View source ↗ - News (RSS)investing·48d ago·Neutral
Why is Vaxcyte stock sliding in after-hours trading today?
View source ↗ - News (RSS)seekingalpha·48d ago·Neutral
Vaxcyte files separate $500M offerings for equity/pre-funded warrants and 2032 convertible notes
View source ↗ - News (Marketaux)seekingalpha.com·48d ago·Positive
Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate - Slideshow (NASDAQ:PCVX) 2026-10-05 Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate - Slideshow (NASDAQ:PCVX) 2026-10-05
View source ↗ - News (RSS)seekingalpha·48d ago·Neutral
Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate - Slideshow
View source ↗ - Newsglobenewswire.com·48d ago·Negative
…posed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes SAN CARLOS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of $500 million of its common stock and pre-funded warrants and $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in separate public offerings registered under the Securitie…
View source ↗ - Newsseekingalpha.com·48d ago·Positive
Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript
View source ↗ - News (RSS)zerohedge·48d ago·Neutral
…+13%, BBD +12%) rallied as Flávio Bolsonaro surged to a surprise lead over Luiz Inácio Lula da Silva in the first round of the presidential election. Vaxcyte shares (PCVX) soar 56% after the pharmaceutical firm said that VAX-31, its experimental vaccine to prevent invasive pneumococcal disease (IPD) and pneumococcal pneumonia, met all primary endpoints in the OPUS-1 pivotal Phase 3 adult trial, compared to PCV20 and PCV21. Virtu Financial Inc. shares (VIRT) are up 3.3% after JPMorgan upgraded th…
View source ↗ - Newsproactiveinvestors.com·48d ago·Neutral
Vaxcyte shares surge on late-stage vaccine trial success Vaxcyte (NASDAQ:PCVX) shares surged 57% in morning trading on Monday after the biotechnology company said its experimental pneumococcal vaccine VAX-31 generated immune responses comparable to rival vaccines in a late-stage study. The results strengthened expectations that VAX-31 could compete with Pfizer's Prevnar 20 and Merck's Capvaxive in the adult pneumococcal vaccine market, which Jefferies estimates could reach $3 billion to $6 billi…
View source ↗ - Newsbarrons.com·48d ago·Neutral
Vaxcyte Stock Spikes 57% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says.
View source ↗ - Newsglobenewswire.com·48d ago·Negative
Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21)
View source ↗ - News (RSS)investing·49d ago·Neutral
Vaxcyte to present phase 3 trial data for vaccine candidate
View source ↗ - Newsglobenewswire.com·49d ago·Neutral
…hase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate SAN CARLOS, Calif., Oct. 04, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced it will host a webcast and conference call tomorrow, October 5, 2026 at 8:00 a.m. ET / 5:00 a.m. PT to present topline data from the OPUS-1 adult pivotal Phase 3 trial evaluating the safety, tolerability and immunogenicity of VAX-31, the Company's 31-valent pneumoco…
View source ↗ - News (RSS)yahoo·66d ago·Neutral
Vaxcyte (PCVX) Brings In Pharma Veterans As Its Big Test Nears
View source ↗ - News (Marketaux)finance.yahoo.com·75d ago·Positive
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know Vaxcyte is a clinical-stage bio[+310 characters]
View source ↗ - News (Marketaux)finance.yahoo.com·75d ago·Positive
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm Vaxcyte, Inc. is a cli[+207 characters]
View source ↗ - Newsfool.com·75d ago·Negative
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing Andrew Guggenhime surrendered 2,705 shares at $61.18 per share on August 31 and September 2, representing a transaction value of $165,492. The transaction size represents 2% of the total equity stake held before the filing.
View source ↗ - Newsfool.com·75d ago·Positive
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know The transactions represented a combined value of about $378,000 based on weighted average prices of $61.12 per share. Jim Wassil traded shares equal to 4% of the stake held before the filing.
View source ↗ - Newsfool.com·75d ago·Neutral
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm The disposition of 6,289 shares at $61.20 per share represented a transaction value of about $384,900. The transaction involved shares equal to 0.87% of the total equity stake held before the filing, resulting in a minor reduction of the overall position.
View source ↗ - News (RSS)yahoo·77d ago·Neutral
The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble
View source ↗ - News (RSS)investing·80d ago·Neutral
Vaxcyte appoints two executives, narrows trial timeline
View source ↗ - Newsglobenewswire.com·80d ago·Neutral
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data Luis Jodar, Ph.D., Former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases with Extensive Leadership Experience Across Clinical Development and Medical Affairs for Pneumococcal Conjugate Vaccines Prevnar 13 and Prevnar 20, Joins Vaxcyte as Chief Medical Officer
View source ↗ - Newsglobenewswire.com·87d ago·Neutral
Vaxcyte to Participate in Upcoming Investor Conferences SAN CARLOS, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in fireside chats and host one-on-one meetings at the following investor conferences:
View source ↗ - News (RSS)seekingalpha·96d ago·Neutral
Vaxcyte: Not Enough Safety Margin With Current Price
View source ↗ - News247wallst.com·98d ago·Neutral
If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone Seth Klarman's Baupost Group eliminated its entire stake in Vaxcyte (NASDAQ:PCVX | PCVX Price Prediction) during the June quarter, according to the 13F filed August 13, 2026.
View source ↗
Earnings
Tue, Feb 23(in 3 months)
Consensus estimate $-1.93 per share
Typical surprise -8.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-1.99 vs $-2.11beat
- Wed, Aug 5$-1.97 vs $-2.06beat
- Wed, May 6$-2.30 vs $-1.78miss
- Tue, Feb 24$-1.80 vs $-1.53miss
- Tue, Nov 4$-1.56 vs $-1.27miss
- Wed, Aug 6$-1.22 vs $-1.12miss
Estimates and results for PCVX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PCVX officers and directors.
- Bought
- —
- Sold
- $11.6m
0 trades
46 trades
- Dhaliwal Harpreet S.sold
- Dhaliwal Harpreet S.sold
- Dhaliwal Harpreet S.sold
- Cowan Elviasold
- Cowan Elviasold
- Wassil Jimsold
- Wassil Jimsold
- Wassil Jimsold
54 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Sep 7, 2026 (53d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jun 9, 2026 (27d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jun 9, 2026 (28d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed May 7, 2025 (9d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed May 7, 2025 (23d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed May 7, 2025 (22d later)Buy$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Apr 14, 2025 (40d later)Sell$15,001 - $50,000
- Chris Jacobshouse · NY27 · disclosed Jan 20, 2023 (39d later)Sell$1,001 - $15,000
- Chris Jacobshouse · NY27 · disclosed Dec 12, 2022 (34d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
